291 results about "Immune effects" patented technology

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 1D3 for detecting a porcine epidemic diarrhea virus antibody and application of the monoclonal antibody 1D3. The CDR sequences of the heavy chain variable region are respectively shown as SEQ ID NO.1-3, and the CDR sequences of the light chain variable region are respectively shown as SEQ ID NO.4-6. The antibody can specifically recognize PEDV / S1 protein, binding of the antibody can be competitively blocked by a PEDV specific neutralizing antibody in serum, and the antibody is suitable for establishing a blocking ELISA method. A detection tool based on the antibody has high specificity and sensitivity, and the blocking rate to PEDV positive serum is higher than 50%. The invention can be used for preparing a detection kit or evaluating the immune effect of a vaccine, and provides an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention belongs to the technical field of biochemical engineering, and particularly relates to an amitriptyline hapten and a preparation method thereof, an amitriptyline antigen and a preparation method thereof, an antibody, a kit and application. The amitriptyline hapten has a structural formula shown as a formula (I) or a formula (II). Compared with an existing structure, the amitriptyline hapten prepared by the invention has a better immune effect. The obtained antibody is high in titer, strong in specificity and high in affinity, the LOD of amitriptyline by using an Elisa method established by the antibody is 0.013 ng / mL, the IC50 of amitriptyline is 0.865 ng / mL, the quantitative detection range is 0.07-470.3 ng / mL, the detection sensitivity is high, and the linear range is wide.

The invention relates to the technical field of immune carrier microspheres, in particular to an immune carrier microsphere constructed by individualized MHC-II combined polypeptide, a vaccine and application of the immune carrier microsphere and the vaccine. A core comprises microspheres constructed by a plurality of MHC-II binding polypeptides, sequences of the MHC-II binding polypeptides are obtained based on HLA gene typing results of an inoculator, and each HLA gene corresponds to at least one high-affinity MHC-II binding polypeptide; a shell is a glucan with sulfydryl or other polymer coating layer, and sulfydryl is used as a coupling group to be connected with an antigen to construct the vaccine. The method has the advantages that competition is avoided, inhibition is generated, a better immune effect is achieved, antibodies of high-titer carrier molecules are not generated, and cross reaction side effects are avoided. The carrier molecular diversity is reduced; side effects are avoided. And antibody immunity and cellular immunity functions are generated. The particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants. The preparation process is simple to operate and good in repeatability.

The invention relates to the technical field of biological medicines, in particular to a recombinant rabies virus nano-antibody fused with a solubilizing oligopeptide and a cell penetrating peptide and application of the recombinant rabies virus nano-antibody in preparation of rabies prevention and treatment products. The recombinant rabies virus nano-antibody fused with the solubilizing oligopeptide and the cell penetrating peptide comprises a humanized rabies virus nano-antibody, and the C end of the humanized rabies virus nano-antibody is fused with a solubilizing tag peptide P17 and the cell penetrating peptide. The recombinant rabies virus nano antibody utilizes a prokaryotic expression system, is low in cost, has excellent cell membrane and BBB penetrating ability, can enter a central nervous system from veins for virus neutralization treatment, and has an efficient passive immune effect.

The present invention discloses a vaccine adjuvant, a vaccine composition, and a preparation method and application thereof, relating to the field of veterinary technology. The present invention uses safe, stable, and efficient lipophilic and hydrophilic surfactants, which can reduce the body's side effects and accumulation in the body, and has the technical advantage of high safety. The invention helps to improve the quality of veterinary vaccines and reduce the production costs of veterinary vaccine manufacturers. After the vaccine adjuvant is prepared into a vaccine composition, it can effectively enhance the immunogenicity of the vaccine, improve the vaccine's immune effect, and provide long-term and stable immune protection.

The invention relates to the technical field of mRNA vaccines, and discloses a feline infectious peritonitis mRNA vaccine as well as a preparation method and application thereof. The feline infectious peritonitis mRNA vaccine comprises mRNA molecules; the mRNA molecule comprises an FIBV-S protein coding sequence as shown in SEQ ID NO: 6. According to the invention, the mRNA sequence for coding the natural FIBV-S protein is modified, so that the FIBV-S protein obtained by translation can be stably maintained at the prefusion conformation and has higher immunogenicity, thereby endowing the mRNA vaccine with a better immune effect and being beneficial to the prevention of feline infectious peritonitis.

The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention discloses an echinococcosis mRNA (messenger Ribonucleic Acid) vaccine as well as a preparation method and application thereof. The preparation method of the mRNA vaccine for the echinococcosis comprises the following steps: carrying out codon optimization on a modified target antigen protein, then assembling the modified target antigen protein with 5 'UTR, 3' UTR and Poly (A) tail, carrying out gene synthesis, then cloning the synthesized gene into a pUC57 plasmid, and sequentially carrying out plasmid linearization, in-vitro transcription and purification on the constructed recombinant plasmid to prepare an mRNA molecule, thereby obtaining the mRNA vaccine for the echinococcosis. Finally, mRNA molecules are wrapped in lipid nanoparticles through a microfluidic method to form the mRNA vaccine for the echinococcosis, and immune effect evaluation is carried out on the mRNA vaccine for the echinococcosis. Experiments prove that the prepared mRNA vaccine for the echinococcosis can activate humoral immunity and cellular immunity of mice at the same time, can provide an effective protection effect for the mice attacking insects, and has a wide application prospect in the aspect of preventing and / or treating the echinococcosis.

The invention relates to a monoclonal antibody DIDA55 aiming at hog cholera virus, and a preparation method and application thereof, belonging to the field of medical preparations. The monoclonal antibody DIDA55 or an antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, amino acid sequences of LCDR1, LCDR2 and LCDR3 in a light chain variable region of the antibody are shown as 24th to 34th, 50th to 56th and 89th to 97th in SEQ ID No: 4; amino acid sequences of HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of the antibody are shown as the 31st to 35th, the 50th to 65th and the 95th to 102th of SEQ ID No: 5. The monoclonal antibody provided by the invention can be used in the fields of swine fever E2 protein labeled subunit vaccine immunity, serological diagnosis of wild strains, swine fever vaccine immune effect evaluation, related experiments and the like, and provides antibody resources for prevention, control and purification of CSF.

The invention relates to the technical field of biological medicines, in particular to a vaccine for treating or preventing hepatitis B virus infection. The vaccine comprises a hepatitis B surface antigen and a composite adjuvant, wherein the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21, and the composite adjuvant is prepared from CpG oligodeoxynucleotide and saponin QS-21; the nucleotide sequence of the CpG oligodeoxynucleotide is as shown in SEQ ID NO. 1. According to the vaccine provided by the invention, an HBsAg antibody can be generated in a normal mouse body, and HBV in an HBV-carrier mouse can be effectively eliminated, so that the vaccine has the effect of treating or preventing hepatitis B virus infection. According to the vaccine provided by the invention, two adjuvants, namely CpG oligodeoxynucleotide and saponin QS-21, are adopted, so that the vaccine can be used for synergistically activating an immune effect, enhancing the activation of B cells and permanently transforming into plasma cells, and meanwhile, the vaccine can be used for resisting immune tolerance of T cells, realizing the removal of hepatitis B viruses and realizing functional cure of clinical hepatitis B treatment.

The invention discloses a dual-targeting macrophage membrane nano system and a preparation method and application thereof, and belongs to the field of biological medicine, MKA is wrapped in a macrophage membrane after AuNPs and mitochondrial targeting peptide KLA are connected. The preparation method comprises the following steps: firstly synthesizing AuNPs and modifying, and then wrapping with a macrophage membrane. In treatment, the compound can realize double targeting of tumor cells and mitochondria, enhance radiation-induced DNA damage, inhibit DDR, activate immune pathways and promote T cell infiltration, and can also consume glutathione and amplify oxidative stress to enhance immune effect, and the dose enhancement ratio of the compound in cooperation with 8GyX-rays reaches 3.1. In addition, the MKA is good in biocompatibility in vivo, long in blood circulation time, high in tumor targeting and capable of being quickly cleared through the kidney. The invention provides a new way for tumor radioimmunotherapy, and is helpful for promoting the progress of clinical tumor treatment.

The invention is applicable to the technical field of biomedicine, and provides a preparation method and application of a multifunctional nano composite material. The material has good biocompatibility and can be used as a safe preparation for tumor treatment; the preparation is simple, green and pollution-free; the application of the quercetin in anti-tumor immunotherapy is expanded; the probe has excellent fluorescence / computed tomography dual-mode imaging performance, and can be used for determining tumor boundaries and realizing accurate treatment guidance; the nano-material has excellent photo-thermal and photo-thermal enhanced catalytic performance, has the advantages of being minimally invasive, efficient, small in toxic and side effect, controllable and the like, and can effectively treat primary, metastatic or recurrent head and neck squamous cell carcinoma by activating immunity; by inducing tumor cells to release 2 '3'-cGAMP and preventing the 2 '3'-cGAMP from being degraded, a cGAS-STING signal channel is efficiently activated, and finally the anti-tumor immune effect is enhanced.

The invention provides synthesis of a T-2 toxin antigen and preparation and application of a monoclonal antibody. Relates to the technical field of biotoxin detection. The preparation method of the T-2 toxin antigen comprises the following steps: step 1, synthesizing an immunogen T-2-BSA by adopting a carbodiimide method, dissolving 2mg of T-2 adipic acid with 0.5 mL of dimethylformamide, and recording as a solution A; 5 mg of bovine serum albumin and 3 mg of EDC are dissolved with a 2-morpholine ethanesulfonic acid buffer solution with the pH being 5.5, and the solution is marked as a solution B; step 2, under the condition of stirring, dropwise adding the solution A into the solution B, stirring for 18 hours in a dark place at 4 DEG C, then dialyzing for 3 days by using a phosphate buffer solution, changing the solution once a day, centrifuging the dialysate for 10 minutes at 3,500 r / min, and discarding the precipitate; the adipic acid is coupled with the T-2 toxin through a chemical method, and the unique step enriches the structural characteristics of the hapten, so that the prepared T-2 toxin complete antigen is excellent in immune effect, can efficiently excite immune response of an organism, and shows high specificity and sensitivity.

The invention belongs to the technical field of immunological detection, and particularly relates to an antibody for resisting porcine pseudorabies virus glycoprotein gB and application of the antibody. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The antibody and the PRV glycoprotein gB have good reactivity, recognition specificity and binding sensitivity, the detection sensitivity and accuracy of the gB protein or the anti-gB protein antibody are improved, and an antibody tool with excellent performance is provided for qualitatively or quantitatively evaluating the immune effect of swine herd vaccines and detecting the content of porcine pseudorabies virus antigens in a sample.

The invention relates to the technical field of biological medicine, in particular to a vaccine adjuvant containing saponin and a preparation method of the vaccine adjuvant. The vaccine adjuvant containing saponin is prepared from the following raw materials in percentage by mass: 0.05 to 0.2 percent of saponin components, 0.5 to 2.0 percent of phospholipid, 3 to 7 percent of oil phase, 0.5 to 2.5 percent of surfactant, 0.05 to 0.2 percent of antioxidant, 2.5 to 4.0 percent of trehalose, 0.1 to 0.5 percent of novel synergistic polymer and the balance of water for injection, according to the preparation method disclosed by the invention, an innovative preparation process of firstly preparing blank nanoemulsion and then loading saponin is adopted, and a stable protective layer is formed on the interface of the nanoemulsion, so that hemolytic groups of the saponin are effectively shielded, the toxic and side effects of the saponin are remarkably reduced, and the chemical stability of the saponin is protected. The adjuvant disclosed by the invention is good in stability, high in safety and strong in immune effect, and has a good clinical application prospect.

The invention discloses a vaccine composition and a preparation method thereof, the vaccine composition comprises a first component and a second component, the first component is a recombinant protein antigen, the second component is an oil-in-water composite adjuvant, and the oil-in-water composite adjuvant comprises a water phase, an oil phase, an emulsifier, a Toll-like receptor stimulant and / or an STING stimulant. The vaccine composition provided by the invention can stimulate a body to generate a high-level specific IgG antibody and a neutralizing antibody, and has a good cellular immune effect at the same time. The second component provided by the invention is simple in preparation process, low in cost, stable in dosage form, easy to store and good in immune effect, and has a wide application prospect in vaccine or drug development.

The invention discloses a self-emulsifying adjuvant of a vaccine and a preparation method of the self-emulsifying adjuvant, and relates to the technical field of vaccine adjuvants. The adjuvant comprises an oil phase, an emulsifier and a freeze-drying protective agent, the oil phase comprises squalene and tocopherol, the emulsifier comprises polysorbate and a polyoxyethylene-polyoxypropylene block copolymer, and the freeze-drying protective agent comprises sugar and sugar alcohol. The preparation method comprises the following steps: emulsifying an oil phase and a water phase to form a nano-emulsion, and then freeze-drying to obtain freeze-dried powder. The adjuvant has the advantages of small particle size, uniform distribution, high stability, rapid reconstruction and the like, and can effectively maintain active components and improve the immune effect of vaccines.

The invention discloses an NK cell culture solution and an NK cell culture. The culture solution comprises a cell activation culture solution and a cell amplification culture solution, the cell activation culture solution comprises a basic culture medium, and the basic culture medium contains autologous plasma with the final concentration of 1-10%, IL-2 with the final concentration of 50-1000U / mL, IL-15 with the final concentration of 1-15ng / mL, OK432 with the final concentration of 0.1-1ug / mL and ginseng exosome with the final concentration of 1-10ug / mL; the cell amplification culture solution comprises a basic culture medium, and the basic culture medium contains IL-2 with the final concentration of 100-2000U / mL. The ginseng exosome component in the cell culture fluid can promote NK cell proliferation and remarkably improve the immune killing function of the NK cells, and the ginseng exosome serving as an activating factor can effectively improve the activity of the NK cells and enhance the immune effect of the NK cells.

The invention discloses a porcine reproductive and respiratory syndrome virus mRNA (messenger Ribonucleic Acid) molecule and application thereof, and four mRNA vaccines GP35m-LNP, GP45m-LNP, GP345m-LNP and GP2345m-LNP are designed by combining structural protein GP2a, GP3, GP4 and GP5 genes of a PRRSV FJ1402 strain of NADC30-like. Mouse test results show that the GP345m-LNP can simultaneously induce strong humoral and cellular immune response, the GP2345m-LNP is secondary, and the effect is superior to that of an inactivated vaccine (only inducing humoral immunity). After immunization, the PRRSV FJ1402 strain is adopted for counteracting toxic substances, the virus load in blood and lungs of a GP345m-LNP group is obviously reduced, pathological injuries of the lungs are obviously relieved, the immune effect is superior to that of an inactivated vaccine group, and the vaccine has a relatively good application prospect.

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.

The invention relates to a cationized manganese nano adjuvant as well as a preparation method and application thereof. The cationized manganese nano adjuvant comprises manganous-manganic oxide nano particles and cationized template molecules wrapping the surfaces of the manganous-manganic oxide nano particles, the cationization template molecule is a protein subjected to cationization modification treatment, or a protein fragment thereof, or a polypeptide fragment thereof. Precise regulation and control of surface charges and structures of the manganese nanoparticles are realized through a biomineralization technology, and the key problems of a traditional vaccine adjuvant in the aspects of antigen delivery, immune activation and biocompatibility are effectively solved. The cationized manganese nano adjuvant can efficiently adsorb various antigens to form a stable nano vaccine compound, and congenital immunity and adaptive immunity response of an organism can be remarkably activated; lymph nodes can be effectively targeted, the enrichment degree of antigens in the lymph nodes is improved, and the immune effect is further enhanced; meanwhile, the biotoxicity is low, and the stability is excellent.

The invention discloses a neutralizing swine monoclonal antibody pO18-40 and a neutralizing swine monoclonal antibody pO18-43 for foot and mouth disease virus type O. The amino acid sequences of a heavy chain variable region (VH) and a light chain variable region (VL) of the antibody pO18-40 are respectively as shown in SEQ ID No. 1 and SEQ ID No. 2; the amino acid sequences of VH and VL of the antibody pO18-43 are respectively as shown in SEQ ID No. 3 and SEQ ID No. 4. The antibody obtained by the invention is a full-swine-source antibody, can specifically neutralize the classical strain of the O-type foot-and-mouth disease virus, and can clearly distinguish the classical strain of the O / Cathay topological type from the variant strain of the O / Cathay topological type. A key antigen epitope recognized by the antibody is located at the 149th amino acid of a VP1 protein G-H ring, and the site is a key site of O / Cathay strain antigen variation and vaccine immune protection. The antibody provided by the invention provides an important tool and theoretical basis for serological detection of O-type FMDV, vaccine immune effect evaluation and optimal design of broad-spectrum vaccines.

The invention is applicable to the field of genetic engineering, and provides a mycobacterium tuberculosis Mce1A-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis Mce1A protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. The Mce1A-LS protein nanoparticle provided by the invention is high in immunogenicity, the protein Mce1A with high immunogenicity can induce to generate a synergistic immune effect and is high in safety, and the expressed fusion protein is non-toxic and harmless, so that the biosafety is high, in addition, the immune effect of the Mce1A-LS protein nanoparticle is good, and after the Mce1A-LS protein nanoparticle is used for immunizing a mouse, the immunogenicity of the Mce1A-LS protein nanoparticle is greatly improved. Strong body fluid and / or cellular immune response can be generated, which indicates that after immunization, a specific immune effect can be generated in a mouse body.

The invention relates to the technical field of immune carriers, in particular to immune carrier microspheres loaded with individualized MHC-II binding polypeptide and vaccine preparation and application of the immune carrier microspheres loaded with the individualized MHC-II binding polypeptide. The core microsphere is loaded with individualized MHC-II binding polypeptide, the sequence of the MHC-II binding polypeptide is obtained by predicting and screening based on an HLA genotyping result, and each HLA allele corresponds to at least one high-affinity MHC-II binding polypeptide; and the shell is a glucan or other polymer coating layer. The preparation method has the advantages that the T epitope and the B epitope are separately subjected to immune competitive inhibition inside and outside the microspheres, so that a better immune effect is obtained. The antibody avoids cross reaction side effects; carrier molecule diversity is reduced, and side effects caused by T cell over-activation are avoided; th1 epitopes and Th2 epitopes can be contained in the microspheres, so that antibody immunity and T cell immunity functions are generated; the particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

The invention discloses a DNA vaccine plasmid of a tembusu virus as well as a construction method and application of the DNA vaccine plasmid, and relates to the technical field of molecular biology. The DNA vaccine plasmid of the tembusu virus comprises an expression vector pcDNA3.1-prME containing a 5AA-STING gene segment, and a DNA vaccine plasmid of the tembusu virus, the 5AA-STING gene segment is a gene segment formed by introducing a coding sequence of five amino acids at the N end of the tembusu virus NS1 on an STING gene segment. The invention further provides a construction method and application of the DNA vaccine plasmid of the tembusu virus, the DNA vaccine plasmid of the tembusu virus is favorable for efficiently assembling into a subvirion with a stronger immune effect, and the DNA vaccine plasmid of the tembusu virus can co-express an immune stimulant STING molecule while expressing the structural protein of the tembusu virus to be assembled into the subvirion, so that the DNA vaccine plasmid of the tembusu virus has a good application prospect. The polypeptide is a key molecule for recognizing a double-stranded DNA signal channel in cells, and the immune protection effect is further enhanced.

The invention discloses an enzyme linked immunosorbent assay kit for detecting an avian infectious laryngotracheitis virus antibody, and a fusion protein and a biological material used by the enzyme linked immunosorbent assay kit. The invention provides a method for preparing a recombinant protein. The method comprises the following steps: expressing a coding gene of the recombinant protein in a cell to obtain the recombinant protein; a gp67 signal peptide and a gD protein extracellular domain are sequentially arranged from the N end to the C end of the recombinant protein; and the gD protein extracellular region is the 85th to 406th sites of the gD protein. The invention also protects the recombinant protein and application of the recombinant protein as an antigen specifically bound with the avian infectious laryngotracheitis virus antibody. The invention also protects application of the protein in preparation of a kit for detecting the avian infectious laryngotracheitis virus antibody. The recombinant protein provided by the invention is used for detecting the ILTV antibody in chicken flock serum, has the advantages of high sensitivity and strong specificity, and is suitable for large-scale epidemiological monitoring and immune effect evaluation.

The invention discloses a virus-like particle coated with an aluminum-containing metal organic framework mineralization layer and application of the virus-like particle. In order to improve the VLPs vaccine stability and immune effect, the invention synthesizes a novel aluminum-containing metal organic framework (ZAM). The ZAM can mineralize the VLPs at a high level under a mild condition to form the VLPs-ZAM nano vaccine. Taking a foot and mouth disease virus (FMDV) virus-like particle (VLPs) vaccine as an example, a heat treatment test shows that ZAM mineralization significantly improves the heat stability of FMDVVLPs, and the effect is superior to that of Al (OH) 3 and ZIF-8. The FMDV VLPs-ZAM not only has the effect of promoting APCs to take in FMDVVLPs, but also can promote antigens to escape from lysosome to cytoplasm due to the pH responsiveness of the FMDV VLPs-ZAM. A mouse immune test shows that ZAM mineralization improves the specific immune response level and stability induced by FMDV VLPs. The invention provides a new technical means for improving the stability of the VLPs vaccine and the immune effect of the VLPs vaccine.